Log In

 

Company Name : Boehringer Ingelheim

Monday, March 20, 2017 4:45PM IST (11:15AM GMT)

(BW)(BOEHRINGER-INGELHEIM)

Uninterrupted Pradaxa® Showed Less Major Bleeding than Warfarin in Atrial Fibrillation Patients Undergoing Catheter Ablation


Ingelheim, Germany

  • In the RE-CIRCUIT® trial, there were less major bleeding and fewer serious adverse events with uninterrupted Pradaxa® than with uninterrupted warfarin1,2
  • Patients studied in the trial were reflective of those undergoing catheter ablation in routine clinical practice, providing highly relevant data to treating physicians1,2
  • Data presented at the ACC Congress 2017 and published in the New England Journal of Medicine (NEJM)1,2


Important new data from the RE-CIRCUIT® study show a better safety profile for Pradaxa® (dabigatran etexilate) compared to warfarin in atrial fibrillation (AF) patients undergoing catheter ablation. AF patients who underwent catheter ablation while being treated with uninterrupted Pradaxa® experienced less major bleeding and fewer serious adverse events compared to those treated with uninterrupted warfarin. The results were presented in a late-breaking session at the American College of Cardiology 66th Annual Scientific Session in Washington and simultaneously published in the New England Journal of Medicine.1,2

 

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170320005458/en/

 

In the RE-CIRCUIT® trial, uninterrupted Pradaxa® significantly reduced the risk of major bleeding complications compared with uninterrupted warfarin: The trial showed a 5.3% absolute risk reduction in its primary endpoint, with major bleeds occurring in 5/317 of patients receiving Pradaxa® versus 22/318 of patients receiving warfarin (77.2% relative risk reduction). Pradaxa® showed a similar incidence of minor bleeding complications compared to warfarin (59/317 versus 54/318). There were no thromboembolic events in patients taking Pradaxa® and one in patients taking warfarin. 635 patients with paroxysmal or persistent AF undergoing catheter ablation were included in the RE-CIRCUIT® trial. These patients were reflective of the types of patients undergoing the procedure in routine clinical practice, providing relevant new data to treating physicians.1,2

 

“These results are exciting news for the medical community,” said Professor Hugh Calkins, Chairman of the RE-CIRCUIT® Study Steering Committee and Professor of Cardiology and Director of the Electrophysiology Laboratory and Arrhythmia Service, Johns Hopkins Hospital, Baltimore, USA. “During an ablation procedure, patients are at risk of potential major complications, including stroke and bleeding. Therefore anticoagulation management at the time of AF ablation is critically important. In RE-CIRCUIT, we have seen that uninterrupted anticoagulation with dabigatran showed significantly lower major bleeding complications than warfarin in atrial fibrillation patients undergoing cardiac ablation.”

 

Every year more than 200,000 ablation procedures are conducted globally in patients with AF3-5, the most common heart rhythm irregularity.6 Ablation is a common treatment for the irregular heart beat experienced by AF patients.7 The procedure involves passing a catheter through a vein or artery in the groin or arm into the heart and then using radiofrequency energy, extreme heat or extreme cold energy to destroy or isolate the area that is generating the abnormal heart rhythm.7 Catheter ablation is associated with a risk of both thromboembolism and bleeding.8,9 Anticoagulation before, during, and after ablation needs to be carefully managed to minimise these risks.10,11 RE-CIRCUIT® has now provided specific data on this clinical situation for Pradaxa®, a non-vitamin K antagonist oral anticoagulant (NOAC).1,2

 

“Once again Pradaxa® has shown safety benefits for patients compared to warfarin,” said Professor Jörg Kreuzer, Vice President Medicine, Therapeutic Area Cardiovascular, Boehringer Ingelheim. “Only one patient taking Pradaxa® required a medical intervention or procedure due to a major bleeding compared to eleven patients taking warfarin. And even in this one patient, the use of the specific reversal agent for Pradaxa® was not needed, although it was available to study investigators.”

 

RE-CIRCUIT® is part of Boehringer Ingelheim’s innovation in anticoagulation care for patients and physicians. Boehringer Ingelheim launched Pradaxa®, the first NOAC for stroke risk reduction in patients with AF12,13, and in 2015 gained approval for idarucizumab (Praxbind®), the first specific NOAC reversal agent for use in emergency situations to reverse the anticoagulant effect of dabigatran.14,15 Idarucizumab is widely available and stocked in over 7,500 hospitals worldwide, including in the United States, the European Union and Japan.16

 

~ENDS~

 

Please click on the link below for ‘Notes to Editors and References’:

 

https://www.boehringer-ingelheim.com/press-release/ACC17-RE-CIRCUIT

 

FOR MEDIA ONLY: Exclusive content on RE-CIRCUIT study now available. Confirm your profession here bit.ly/2eXaMEq to access #ACC17

 

 

 

 
MULTIMEDIA AVAILABLE :
http://www.businesswire.com/news/home/20170320005458/en/


Click here for Media Contact Details
CONTACTS : Boehringer Ingelheim GmbHFriederike MiddekePhone: +49 6132 – 77 141575Fax: +49 6132 – 77 6601E-mail: press@boehringer-ingelheim.comTwitter: http://twitter.com/BoehringerorMore informationwww.boehringer-ingelheim.com

More News from Boehringer Ingelheim

20/03/2017 5:00PM

Boehringer Ingelheim Phase III study now enrolling patients with progressive fibrosing lung diseases

For the first time, patients with different fibrosing lung diseases will be included in one single clinical trial assessing the efficacy of nintedanib* as a potential treatment The PF-ILD clinical trial is the ...

18/03/2017 9:00AM

First dedicated outcome trials of empagliflozin in chronic heart failure initiated

EMPEROR HF clinical trial programme will evaluate the efficacy and safety of empagliflozin in patients with chronic heart failure, including those with and without type 2 diabetes Heart failure (HF) affects 26 ...

02/03/2017 10:58PM

Boehringer Ingelheim expands collaboration with Vanderbilt University to tackle some of the most difficult-to-treat cancers

Boehringer Ingelheim announced today a new collaboration with Vanderbilt University, Nashville, Tennessee. The multi-year program complements an already existing collaboration by focusing on the research and development ...

Similar News

30/03/2017 6:55PM

IncellDx Releases CE-IVD Quantitative Single Cell PD-L1 OncoTect iO® Assay

IncellDx, Inc. announces the release of their CE marked OncoTect iO® Lung Kit today, March 30, 2017, entering the immunotherapeutic diagnostic market in Europe and countries that accept the CE- mark and declaration ...

No Image

30/03/2017 6:40PM

Takeda's Dengue Vaccine Candidate Elicited Broad Immune Responses in Children and Adolescents Living in Dengue-Endemic Areas; Interim Phase 2 Analysis Published in The Lancet Infectious Diseases

Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) today announced that data from a 6-month interim analysis* of the ongoing DEN-204 trial of its live-attenuated tetravalent dengue vaccine ...